Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

LCTB-21: A DYRK1A protein kinase inhibitor for treatment of cognitive decline in Down Syndrome.

Project description

A novel drug to restore cognitive ability in Down syndrome patients

Down syndrome is a genetic disorder caused by the presence of an extra chromosome 21. People with Down syndrome have mild to moderate cognitive and learning deficits as well as certain physical features. Emerging evidence indicates that cognitive decline is due to the over-expression of the DYRK1A kinase in the brain. In neurons, the DYRK1A protein is involved in the formation and maturation of dendrite extensions which transmit nerve impulses. Funded by the European Innovation Council, the DOWN-AUTONOMY project will develop an inhibitor against DYRK1A protein as a novel therapeutic to reduce symptoms in Down syndrome patients.

Objective

All people with Down Syndrome (DS) suffer from a certain level of impaired learning and memory (cognitive disorders) from childhood onwards, greatly impacting their autonomy and societal integration. This is becoming an increasingly urgent issue as people with DS are more often outliving their care takers, yet an adequate treatment has not yet been developed.

Studies have revealed that the cognitive decline in people with DS is associated with overexpression of the DYRK1A protein kinase in the brain. Perha Pharmaceuticals has developed a novel therapeutic compound, Leucettinib-21 (LCTB-21), which acts as a DYRK1A inhibitor that can reduce cognitive decline in children with DS. Ultimately, this will increase the autonomy of people with DS resulting in better societal integration.

Perha Pharmaceuticals aims to outlicense LCTB-21 to a large pharmaceutical partner (e.g. Otsuka Pharmaceuticals, Intra-Cellular Therapies) following a successful phase 2a clinical trial.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

PERHA PHARMACEUTICALS SAS
Net EU contribution
€ 2 500 000,00
Address
LIEUDIT PRESQUILE DE PERHARIDY BATIMENT 1
29680 ROSCOFF
France
SME
Yes
Region
Bretagne Bretagne Finistère
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 11 359 709,00